Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) Director Atul Pande sold 3,000 shares of Immunovant stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $36.00, for a total transaction of $108,000.00. Following the sale, the director owned 116,731 shares of the company’s stock, valued at approximately $4,202,316. This represents a 2.51% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Atul Pande also recently made the following trade(s):
- On Friday, August 28th, Atul Pande sold 1,500 shares of Immunovant stock. The shares were sold at an average price of $43.27, for a total transaction of $64,905.00.
Immunovant Price Performance
Shares of IMVT stock traded down $0.87 during trading hours on Friday, hitting $34.18. The company had a trading volume of 864,711 shares, compared to its average volume of 1,477,899. The stock has a market capitalization of $7.07 billion, a PE ratio of -13.35 and a beta of 0.95. The company’s fifty day moving average is $32.64 and its 200 day moving average is $32.33. Immunovant, Inc. has a fifty-two week low of $21.86 and a fifty-two week high of $45.42.
Immunovant (NASDAQ:IMVT – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.27. During the same quarter last year, the company posted ($0.73) earnings per share. Equities analysts forecast that Immunovant, Inc. will post -2.78 earnings per share for the current year.
Institutional Investors Weigh In On Immunovant
Several large investors have recently added to or reduced their stakes in IMVT. Marshall Wace LLP lifted its holdings in Immunovant by 141.0% during the 3rd quarter. Marshall Wace LLP now owns 343,341 shares of the company’s stock worth $11,598,000 after buying an additional 200,853 shares in the last quarter. Gabelli Funds LLC purchased a new position in Immunovant in the 3rd quarter valued at approximately $338,000. First Trust Advisors LP grew its stake in shares of Immunovant by 22.6% in the third quarter. First Trust Advisors LP now owns 6,625 shares of the company’s stock worth $224,000 after acquiring an additional 1,220 shares in the last quarter. Private Advisor Group LLC acquired a new position in shares of Immunovant in the third quarter worth $488,000. Finally, Voya Investment Management LLC grew its stake in shares of Immunovant by 6.5% in the third quarter. Voya Investment Management LLC now owns 93,726 shares of the company’s stock worth $3,166,000 after acquiring an additional 5,733 shares in the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on IMVT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunovant in a research note on Friday, October 2nd. Wells Fargo & Company increased their target price on Immunovant from $45.00 to $47.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 10th. Truist Financial increased their target price on Immunovant from $30.00 to $33.00 and gave the stock a “hold” rating in a research note on Tuesday, November 10th. Sanford C. Bernstein upgraded Immunovant to a “hold” rating in a report on Wednesday, July 29th. Finally, Wall Street Zen raised Immunovant from a “sell” rating to a “hold” rating in a research report on Saturday. Nine equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $44.60.
View Our Latest Analysis on Immunovant
About Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.
Featured Articles
- Five stocks we like better than Immunovant
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.
